drugset
drugset / Trial / NCT06926634

Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

NCT06926634 ↗

Phase 2 Recruiting 32 enrolled Washington University School of Medicine Exelixis · collab
NaSingle-groupOpen-labelTreatment

Summary

The investigators hypothesize that zanzalintinib maintenance therapy after initial cytotoxic chemotherapy can prolong the progression-free survival (PFS) in patients with high-grade NENs.

Timeline

Start
2025-12-09
Primary completion
2034-12-31
Completion
2034-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Zanzalintinib Small molecule 60 mg Oral

Indications

neuroendocrine neoplasm